Mysoline

Utilized to target uncontrolled seizure activity, this anticonvulsant is indicated to alleviate the frequency and severity of various epilepsy types.

Strengths: 250mg

Medicine details

Conditions
Therapeutic class

Antiepileptic

Pharmacological class

Barbiturate

Known off-label uses

essential tremor

Contraindications

hypersensitivity to primidone; porphyria

Precautions and warnings

avoid abrupt withdrawal; may cause drowsiness; monitor blood counts periodically

Minor side effects

sedation; dizziness; fatigue; ataxia

Moderate side effects

nystagmus; lethargy; confusion

Dosage forms

Tablet

Administration route

Oral use

Prescription status

POM

Manufacturer

Concordia International

Onset Time

1–2 hours

Duration

12–24 hours

Storage instructions

Store in dry conditions at room temperature.

Drug interactions

alcohol; cns depressants; valproate

Age restrictions

Use with caution in children.

Serious side effects

megaloblastic anaemia — requires immediate medical attention; blood dyscrasias — requires immediate medical attention

Patient summary

Utilized to target uncontrolled seizure activity, this anticonvulsant is indicated to alleviate the frequency and severity of various epilepsy types.

Mechanism of action

Primidone is metabolized into phenobarbital and phenylethylmalonamide (PEMA), both of which possess anticonvulsant properties. They enhance GABA-mediated inhibition, suppressing excessive neuronal firing.

Pregnancy and breastfeeding

Pregnancy: Use with extreme caution. Breastfeeding: May cause sedation in infants.

Mysoline

Utilized to target uncontrolled seizure activity, this anticonvulsant is indicated to alleviate the frequency and severity of various epilepsy types.

Editorial Notes

  • Active ingredient(s): Primidone
  • Listed indication(s): Epilepsy

Available option

  • 120 tablets - 250 mg145-250-mg-3655